CASKIN2

Across TCGA pan-cancer cohorts, CASKIN2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CASKIN2 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CASKIN2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CASKIN2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LUAD, PDAC, and GBM are the cancer types where CASKIN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.278	0.819	.004	18	view →
PDAC	OS	Quartile	III,IV	0.775	0.176	.006	5	view →
GBM	OS	Tertile	All	0.434	0.732	.018	4	view →
LSCC	DFS	Quartile	II,III,IV	0.252	0.888	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CASKIN2–LUAD (OS)

Open the LUAD breakdown →